SCHEMBL18779347

SCHEMBL18779347

Nc1cnc2c(c1-c1ccccc1)CCCC2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.51
HSD17B10 Q99714 7/20 0.51
ALDH1A1 P00352 7/20 0.48
ADORA2A P29274 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HPGD P15428 3/20 0.47
BCHE P06276 6/20 0.41
ACHE P22303 5/20 0.41
TSHR P16473 4/20 0.41
CYP1A2 P05177 3/20 0.41
CYP2D6 P10635 3/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2C19 P33261 2/20 0.41
CACNB4 O00305 1/20 0.41
CACNA1A O00555 1/20 0.41
SLC22A2 O15244 1/20 0.41
SLC22A1 O15245 1/20 0.41
ABCC4 O15439 1/20 0.41
CACNA1G O43497 1/20 0.41
CACNG3 O60359 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20368721 0.97 KDM4E (0.51) KDM4EHSD17B10ALDH1A1ADORA2ASMN1; SMN2
SCHEMBL21963241 0.77 ACHE (0.49) KDM4EHSD17B10ALDH1A1ADORA2ASMN1; SMN2
SCHEMBL18779343 0.76 LDHA (0.44) KDM4EHSD17B10ALDH1A1ADORA2ASMN1; SMN2
SCHEMBL17111546 0.73 P2RX7 (0.41) ALDH1A1SMN1; SMN2LMNAHTTPLA2G1B
SCHEMBL30657668 0.73 HSD17B10 (0.58) KDM4EHSD17B10ALDH1A1ADORA2ASMN1; SMN2
SCHEMBL7295408 0.72 ACHE (0.52) KDM4EHSD17B10ALDH1A1BCHEACHE
SCHEMBL22853569 0.71 CYP1A2 (0.47) KDM4EHSD17B10ALDH1A1ADORA2ASMN1; SMN2
SCHEMBL18399566 0.71 ALDH1A1 (0.40) KDM4EHSD17B10ALDH1A1ADORA2ASMN1; SMN2
SCHEMBL22018823 0.70 SMN1; SMN2 (0.48) ALDH1A1SMN1; SMN2HPGDADORA3NFKB1
SCHEMBL12884366 0.70 KDM4E (0.67) KDM4EHSD17B10ALDH1A1ADORA2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9815846-B2 TrkA kinase inhibitors, compositions and methods thereof MERCK SHARP & DOHME CORP. (US) 2017-11-14 US disclosed
US-20170114071-A1 TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF MERCK SHARP & DOHME CORP. (US) 2017-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170114071-A1 TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF NGFR, NGF, NTRK1 KDM4E 3594/4885HSD17B10 3700/4885ALDH1A1 4290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.